CRVS
HealthcareCorvus Pharmaceuticals, Inc. · Biotechnology · $1B
What is Corvus Pharmaceuticals, Inc.?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. Based in South San Francisco, it is building a pipeline of investigational medicines targeting cancer and immune-related diseases.
Corvus generates no product revenue at this stage — its business model centers on advancing clinical-stage drug candidates through trials with the goal of eventual commercialization. The company funds its operations through capital raises and a strategic collaboration with Angel Pharmaceuticals. Its pipeline spans multiple cancer types, including lung cancer, head and neck cancers, T-cell lymphomas, and renal cell cancer, using distinct mechanisms such as anti-CD73 antibodies, ITK inhibition, and adenosine pathway blockade.
Corvus Pharmaceuticals was incorporated in 2014 and is headquartered in South San Francisco, California.
- Mupadolimab (CPI-006) — anti-CD73 antibody in Phase Ib/II trials for lung and head and neck cancers
- CPI-818 — ITK inhibitor in Phase I/Ib trials for malignant T-cell lymphomas
- Ciforadenant (CPI-444) — oral A2A receptor antagonist in Phase II for renal cell cancer
- CPI-182 — preclinical antibody targeting inflammation and myeloid suppression
- CPI-935 — preclinical adenosine A2B receptor antagonist aimed at preventing fibrosis
Is CRVS a Good Stock to Buy?
UQS Score rates CRVS as Poor overall, reflecting the early-stage nature and inherent uncertainties of its clinical pipeline.
The Risk pillar stands out as the relative bright spot within the CRVS profile, suggesting the company's balance sheet and near-term financial structure carry less immediate distress than many clinical-stage peers. This provides some runway for pipeline advancement.
Quality, Moat, and Growth all register as Weak, which is typical for pre-revenue biotechs but signals meaningful uncertainty. Valuation is rated Elevated, meaning the current market price may not offer a margin of safety relative to the company's development stage.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CRVS pay dividends?
No — Corvus Pharmaceuticals, Inc. does not currently pay a dividend.
Corvus Pharmaceuticals does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward funding clinical trials and research operations. Income-focused investors should look elsewhere; CRVS is a pure pipeline-driven story where value, if realized, would come from drug development milestones rather than distributions.
When does CRVS report earnings?
Corvus Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline updates and trial readouts tend to be more market-moving than the financial statements themselves.
For the most recent quarter's results and pipeline updates, visit Corvus Pharmaceuticals' investor relations page directly.
CRVS Price History
+525.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Corvus Pharmaceuticals, Inc.?
Based on Corvus Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CRVS Long-term Outlook
The fundamental outlook for CRVS is shaped almost entirely by clinical trial outcomes. With Growth and Quality both rated Weak, near-term catalysts depend on trial readouts rather than commercial execution. The Good Risk rating suggests the company has managed its financial position with some discipline, but the Elevated Valuation label indicates the market may already be pricing in optimistic scenarios. Progress in any of its three active clinical programs could shift the trajectory meaningfully.
Growth drivers
- Positive Phase II data from Ciforadenant in renal cell cancer could accelerate development timelines
- Expansion of Mupadolimab trials into additional cancer indications or combination regimens
- Strategic collaboration with Angel Pharmaceuticals providing development support and potential milestone payments
Key risks
- Clinical trial failure in any lead program would significantly impair the pipeline's value
- Elevated Valuation relative to development stage leaves limited room for disappointment
- Ongoing cash consumption without product revenue creates continued dilution risk for shareholders
CRVS vs Peers
Corvus operates in a crowded clinical-stage biotech landscape alongside other small-cap companies advancing novel therapeutic platforms.
Wave focuses on RNA-based medicines using its stereopure chemistry platform, targeting neurological and other diseases rather than oncology.
Maze uses human genetics to identify and validate drug targets, with a pipeline oriented toward rare and common diseases distinct from Corvus's immuno-oncology focus.
Novavax is a more mature vaccine-focused biotech with an approved product, giving it a commercial revenue base that Corvus currently lacks.
Frequently Asked Questions
What does Corvus Pharmaceuticals do?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapies. Its pipeline includes drug candidates targeting non-small cell lung cancer, head and neck cancers, T-cell lymphomas, and renal cell cancer through mechanisms such as CD73 blockade, ITK inhibition, and adenosine receptor antagonism. The company has not yet commercialized any product.
Does CRVS pay dividends?
No, Corvus Pharmaceuticals does not pay a dividend. Pre-revenue clinical-stage biotechs typically reinvest all available capital into research and trial operations. Investors in CRVS are betting on pipeline success rather than income generation.
When does CRVS report earnings?
Corvus Pharmaceuticals follows a standard quarterly reporting cadence for US-listed companies. Because it is pre-revenue, the most watched disclosures are clinical updates rather than financial results. Check the company's investor relations page for the current reporting schedule.
Is CRVS a good stock to buy?
UQS Score rates CRVS as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The relative strength lies in the Risk pillar. Whether CRVS fits a portfolio depends on an investor's tolerance for clinical-stage biotech risk. The full pillar breakdown is available to Pro members.
Is CRVS overvalued?
The UQS Valuation pillar for CRVS is rated Elevated, suggesting the current market price may not offer a comfortable margin of safety given the company's pre-revenue, clinical-stage status. Valuation in biotech is heavily tied to pipeline probability assumptions, which carry significant uncertainty.
How does CRVS compare to its competitors?
Compared to peers like Wave Life Sciences and Maze Therapeutics, Corvus is similarly early-stage but differentiated by its immuno-oncology focus and adenosine pathway programs. Novavax, by contrast, has an approved vaccine product, placing it at a more advanced commercial stage than Corvus.
What is CRVS's market cap bracket?
Corvus Pharmaceuticals is classified as a small-cap company. This reflects its early development stage and pre-revenue status, which is typical for clinical-stage biotechs advancing multiple candidates through trials simultaneously.
Who founded Corvus Pharmaceuticals?
Corvus Pharmaceuticals was incorporated in 2014. Founding and leadership details are publicly available through the company's official filings and investor relations materials, which provide the most accurate and current information.
Is CRVS a long-term buy?
As a long-term quality indicator, CRVS scores Poor on the UQS composite, with Weak readings across Quality, Moat, and Growth. Long-term value would depend almost entirely on clinical trial success and eventual commercialization — outcomes that carry substantial binary risk at this stage.
What is the main competitive advantage of Corvus Pharmaceuticals?
Corvus's differentiation lies in its focus on the adenosine pathway and CD73 biology within immuno-oncology — a mechanistic niche with limited direct competition. However, the UQS Moat pillar is rated Weak, reflecting that without approved products or commercial revenue, durable competitive advantages remain unproven.
What sector does CRVS belong to?
Corvus Pharmaceuticals operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals and immuno-oncology. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Is CRVS a growth stock or value stock?
CRVS carries a Weak Growth pillar rating and an Elevated Valuation rating, which makes it difficult to classify as either a traditional growth or value stock. It is better described as a speculative clinical-stage biotech where returns hinge on binary trial outcomes rather than sustained earnings growth.
Unlock Full CRVS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for CRVS
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare CRVS against sector peers on quality and risk
- ✓Screen for clinical-stage biotechs with stronger UQS profiles
- ✓Get the full analyst view available only to Pro members
Pro Analysis
CRVS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 16.1 | 0.0 | 9.0 | 18.5 | 67.5 | 0.0 | +3.7 |
| May 9, 2026 | 12.4 | 0.0 | 9.0 | 0.0 | 67.5 | 0.0 | -3.7 |
| May 8, 2026 | 16.1 | 0.0 | 9.0 | 18.5 | 67.5 | 0.0 | -1.0 |
| Apr 22, 2026 | 17.1 | 0.0 | 9.0 | 18.5 | 74.4 | 0.0 | -0.9 |
| Apr 2, 2026 | 18.0 | 0.0 | 9.0 | 23.1 | 74.4 | 0.0 | — |
CRVS — Pillar Breakdown
Quality
— 0.0/100 (25%)Corvus Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Corvus Pharmaceuticals, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 67.5/100 (15%)Corvus Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Corvus Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Corvus Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CRVS.
Score Composition
Financial Data
More Stock Analysis
How is the CRVS UQS Score Calculated?
The UQS (Unified Quality Score) for Corvus Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Corvus Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Corvus Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.